NCT00590031View on ClinicalTrials.gov

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Esophageal Carcinoma
Interventions
DRUG

Cisplatin

pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12

DRUG

Irinotecan

Irinotecan will be given 65 mg/m2

RADIATION

External Beam Radiation Therapy

will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00590031 - Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. | Biotech Hunter | Biotech Hunter